Gynecologic Oncology

A false-positive mammogram result leaves women anxious, but new research shows that the anxiety is short-lived and may have an unintended beneficial effect.

Vaginal atrophy doesn’t have to be a life sentence of painful sex. New research describes a solution for dyspareunia that can take sex from “painful” to “comfortable.”

The FDA has weighed in on the safety of uterine fibroid morcellation. Given the current evidence, find out what they recommend.

The safety of fertility drugs has been a concern to physicians and patients alike. A new study assessing fertility drugs and breast cancer risk has reassuring results.

A recent study in Cancer Epidemiology, Biomarkers & Prevention indicates that the link between breast cancer and fertility drugs may not be as strong as previously suspected.

Digital mammography is superior to screen-film mammography, and the digital technology has other patient benefits as well, a new study finds.

Mammography screening for breast cancer saves lives: this should be the message that physicians spread to colleagues and patients, say leading experts.

The best strategy for identifying pelvic masses and triaging patients to the appropriate surgeons.

New research expected this year will bring about significant changes to clinical practice. Here, society leaders share what’s on their radar for 2014.

What research from the past year will have the most significant impact on women's health care? The leaders of five major ob/gyn societies weigh in.

In a unanimous vote, a Food and Drug Administration (FDA) advisory committee has recommended that the agency give premarket approval to a human papillomavirus (HPV) DNA test as first-line screening for cervical cancer.

Three doses of the quadrivalent HPV vaccine was more effective in preventing high-grade cervical abnormalities than other types and more effective in younger women.

A study by Canadian researchers shows that preventive oophorectomy reduces risk of ovarian, fallopian tube, or peritoneal cancer by 80% in women who have BRCA1 or BRCA2 mutations. Published in The Journal of Clinical Oncology, the report also documented a 77% reduction in all-cause mortality.

In Denmark, researchers found that the risk of atypia, atypia+, and cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) were significantly reduced among women who received the vaccine.

Ovarian cancer is notorious for its late stage at diagnosis and its poor prognosis. In the absence of good screening tests, salpingectomy is the only form of prophylaxis for this cancer.

Adding a monoclonal antibody (MAb)-bevacizumab-to combination chemotherapy may increase survival in patients with recurrent cervical cancer, according to results of a National Cancer Institute-funded randomized trial. Use of bevacizumab in cervical cancer is experimental; the MAb currently is approved to treat metastatic colorectal cancer, non-squamous, non-small cell lung cancer, and glioblastoma.

Two doses of quadrivalent human papillomavirus (HPV) vaccine protects against genital warts nearly as well as the standard 3-dose schedule, according to new study findings.

A daily regimen of low-dose (

Women who take aspirin daily may reduce their risk of ovarian cancer by 20%, new research has found. However, this preventive strategy isn't ready for prime time; additional study is needed before clinical recommendations can be made.

New research, led by Connie Trimble, MD, shows that vaccine treatments for women with high-grade cervical dysplasia can trigger an immune response that may induce some lesions to resolve.

The rationale for annual mammography in women aged 40 to 59 years needs to be reassessed in countries where adjuvant therapy for breast cancer is available.

Can you identify the cause of abnormal vaginal bleeding in this middle-aged woman?

New evidence reveals that there may be a benefit to continuing cervical cancer screening beyond age 65 years.

Women whose cervical cancer screening ceased between ages 50 and 64 years were 6 times more likely than women who were screened to have cervical cancer from ages 65 to 83 years.